TRDA

Entrada Therapeutics, Inc.

• Reuters·1h ago

  Entrada publishes corporate deck outlining DMD, DM1 pipeline catalysts and $5 billion US market opportunity

• Dow Jones·1d ago

  Entrada Therapeutics Is Maintained at Outperform by Oppenheimer

• Benzinga·1d ago

  Oppenheimer Maintains Outperform on Entrada Therapeutics, Raises Price Target to $23

• Reuters·1d ago

  ENTRADA THERAPEUTICS, INC. <TRDA.O>: OPPENHEIMER RAISES TARGET PRICE TO $23 FROM $21

• TipRanks·1d ago

  Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Viridian Therapeutics (VRDN)

• TipRanks·1d ago

  Entrada Therapeutics price target raised to $23 from $21 at Oppenheimer

• Reuters·1d ago

  U.S. RESEARCH ROUNDUP-EQT, Las Vegas Sands, Twilio

• Reuters·4d ago

  Entrada CFO Kory James Wentworth sells $0 million Entrada Therapeutics common shares

• TipRanks·6d ago

  Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA), Apellis Pharmaceuticals (APLS) and MoonLake Immunotherapeutics (MLTX)

• TipRanks·03/30 15:35

  Entrada Therapeutics management to meet with Oppenheimer

• TipRanks·03/23 10:40

  Analysts Are Bullish on These Healthcare Stocks: Entrada Therapeutics Inc (TRDA), CG Oncology, Inc. (CGON)

• Reuters·03/11 20:37

  Entrada Therapeutics CFO Kory James Wentworth Disposes of Common Shares

• Reuters·03/06 21:37

  Entrada Therapeutics CFO Kory James Wentworth Disposes of Common Shares

• Reuters·03/02 22:21

  Entrada Therapeutics Publishes Corporate Presentation on DMD, DM1 and Inherited Retinal Disease Pipeline

• TipRanks·02/27 13:40

  Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Kymera Therapeutics (KYMR) and Argenx Se (ARGX)